Detailes disclosure is attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories reported unaudited Q2 FY26 revenue of Rs. 1,292.63 lakhs, down from Rs. 1,330.12 lakhs in Q2 FY25. Half-year (H1 FY26) revenue stood at Rs. 2,377.99 lakhs versus Rs. 2,519.00 lakhs in H1 FY25, indicating a year-on-year decline of about 5.6%. Profit after tax for Q2 was Rs. 140.36 lakhs (EPS Rs. 1.89) and for H1 was Rs. 136.01 lakhs (EPS Rs. 1.83), a slight dip from the prior year. The statutory auditor (M.A. Shah & Co.) issued an unmodified limited review report, indicating no material concerns. The company operates in a single pharmaceutical segment, and cash flow from operations turned positive at Rs. 101.06 lakhs in H1 FY26 compared to a negative Rs. 215.50 lakhs in H1 FY25, showing improved working capital management.
Revenue has softened year-on-year, but the company swung back to profitability in H1 FY26 after reporting a full-year FY25 loss of Rs. 97.87 lakhs. The clean auditor report and improved operating cash flow are positives, though the top-line decline may temper near-term investor enthusiasm.